Home
SUPN
SUPN News

Latest Supernus Pharmaceuticals Inc. (SUPN) News on November 6, 2025

3 Stocks Under $50 We Steer Clear Of

StockStory

17 days ago

3 Stocks Under $50 We Steer Clear Of

MT Newswires

a month ago

Supernus Pharmaceuticals Insider Sold Shares Worth $1,931,116, According to a Recent SEC Filing

Supernus Pharmaceuticals (SUPN): Is the Current Share Price a Fair Reflection of Its True Valuation?

Simply Wall St.

a month ago

Supernus Pharmaceuticals (SUPN): Is the Current Share Price a Fair Reflection of Its True Valuation?

MT Newswires

a month ago

Supernus Pharmaceuticals Insider Sold Shares Worth $491,485, According to a Recent SEC Filing

Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum?

Simply Wall St.

2 months ago

Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum?

1 Cash-Producing Stock to Research Further and 2 We Brush Off

StockStory

2 months ago

1 Cash-Producing Stock to Research Further and 2 We Brush Off

Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio

Insider Monkey

2 months ago

Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio

Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

StockStory

4 months ago

Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions

Argus Research

4 months ago

SUPN: Lowering target price to $33.00

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years

Simply Wall St.

4 months ago

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years

H.C. Wainwright sees potential competition for Sage from Biogen

TipRanks

5 months ago

H.C. Wainwright sees potential competition for Sage from Biogen

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Zacks

5 months ago

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Zacks

5 months ago

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

TipRanks

5 months ago

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics

Investor's Business Daily

5 months ago

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.

Barrons.com

5 months ago

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.

Supernus makes depression drug play with $795m Sage buyout

Pharmaceutical Technology

5 months ago

Supernus makes depression drug play with $795m Sage buyout

MT Newswires

5 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million

Investor's Business Daily

5 months ago

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million

MT Newswires

5 months ago

Supernus Pharmaceuticals to Acquire Sage for Up to $795 Million in Cash

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

GlobeNewswire

5 months ago

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

3 Small-Cap Stocks Facing Headwinds

StockStory

5 months ago

3 Small-Cap Stocks Facing Headwinds

1 Cash-Producing Stock for Long-Term Investors and 2 to Keep Off Your Radar

StockStory

5 months ago

1 Cash-Producing Stock for Long-Term Investors and 2 to Keep Off Your Radar

Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers

StockStory

5 months ago

Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)

StockStory

5 months ago

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

GlobeNewswire

5 months ago

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

GlobeNewswire

5 months ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

GlobeNewswire

5 months ago

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

3 Cash-Heavy Stocks in the Doghouse

StockStory

6 months ago

3 Cash-Heavy Stocks in the Doghouse

Argus Research

6 months ago

SUPN: Raising target price to $35.00

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals

GlobeNewswire

6 months ago

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals

3 Dawdling Stocks with Mounting Challenges

StockStory

6 months ago

3 Dawdling Stocks with Mounting Challenges

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?

Zacks

6 months ago

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?

Argus Research

6 months ago

SUPN: What does Argus have to say about SUPN?

Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business

Simply Wall St.

6 months ago

Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business

Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

6 months ago

Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

GuruFocus.com

6 months ago

Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

3 Stocks Under $50 That Concern Us

StockStory

6 months ago

3 Stocks Under $50 That Concern Us

Argus Research

6 months ago

SUPN: What does Argus have to say about SUPN?

Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks

6 months ago

Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations

StockStory

6 months ago

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates

Zacks

6 months ago

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates

Supernus Announces First Quarter 2025 Financial Results

GlobeNewswire

6 months ago

Supernus Announces First Quarter 2025 Financial Results

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

StockStory

6 months ago

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

StockStory

6 months ago

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

What Makes Supernus (SUPN) a New Buy Stock

Zacks

6 months ago

What Makes Supernus (SUPN) a New Buy Stock

3 Healthcare Stocks with Mounting Challenges

StockStory

6 months ago

3 Healthcare Stocks with Mounting Challenges

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

GlobeNewswire

6 months ago

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

Argus Research

6 months ago

SUPN: Lowering target price to $32.00

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?

Insider Monkey

7 months ago

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?

Argus Research

7 months ago

SUPN: Raising target price to $33.00

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

StockStory

7 months ago

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

Argus Research

7 months ago

SUPN: Lowering target price to $32.00

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

StockStory

7 months ago

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?

StockStory

7 months ago

Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

StockStory

7 months ago

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

Argus Research

7 months ago

SUPN: Lowering target price to $33.00

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

StockStory

7 months ago

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

Argus Research

7 months ago

SUPN: Raising target price to $35.00

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Investor's Business Daily

7 months ago

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

StockStory

8 months ago

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround

Zacks

8 months ago

Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

StockStory

8 months ago

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

3 Small-Cap Stocks Skating on Thin Ice

StockStory

8 months ago

3 Small-Cap Stocks Skating on Thin Ice

Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

Insider Monkey

8 months ago

Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

Argus Research

8 months ago

SUPN: Lowering target price to $33.00

Supernus to Participate in Two Upcoming Investor Conferences

GlobeNewswire

8 months ago

Supernus to Participate in Two Upcoming Investor Conferences

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

StockStory

8 months ago

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

StockStory

8 months ago

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?

Simply Wall St.

8 months ago

Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?

Insider Monkey

8 months ago

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

8 months ago

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Supernus Pharmaceuticals Inc Earnings Call

MT Newswires

8 months ago

Supernus Pharmaceuticals Q4 Earnings, Revenue Rise; Provides 2025 Revenue Guidance

Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

GuruFocus.com

8 months ago

Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

Argus Research

8 months ago

SUPN: Lowering target price to $34.00

Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

8 months ago

Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates

Zacks

8 months ago

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers

StockStory

8 months ago

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers

Associated Press Finance

8 months ago

Supernus: Q4 Earnings Snapshot

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

8 months ago

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings

StockStory

8 months ago

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Benzinga

9 months ago

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

MT Newswires

9 months ago

Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57

MT Newswires

9 months ago

Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint

Argus Research

9 months ago

SUPN: Raising target price to $42.00

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

GlobeNewswire

9 months ago

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

9 months ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade

Zacks

9 months ago

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade

Supernus wins FDA approval for Parkinson’s pump on fourth try

Pharmaceutical Technology

9 months ago

Supernus wins FDA approval for Parkinson’s pump on fourth try

Argus Research

9 months ago

SUPN: Raising target price to $42.00

MT Newswires

9 months ago

Supernus Pharmaceuticals Says Onapgo Approved by FDA for Parkinson's Disease

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

GlobeNewswire

9 months ago

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

7MM PD market to grow by $4.5bn between 2023 and 2033

Clinical Trials Arena

9 months ago

7MM PD market to grow by $4.5bn between 2023 and 2033

Argus Research

9 months ago

SUPN: What does Argus have to say about SUPN?

MT Newswires

9 months ago

Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

GlobeNewswire

9 months ago

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

Argus Research

9 months ago

SUPN: Raising target price to $41.00

Argus Research

10 months ago

SUPN: Raising target price to $40.00

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years

Simply Wall St.

10 months ago

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years

Share on Social Networks: